Komori
Shin Nippon Biomedical Laboratories (2395) · PolicyRestated

Adoption of the Revenue Recognition Accounting Standard

First written in FY2022-Q1. 1 of 2 entries say "Restated". Latest entry: FY2022-Q3.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022-Q1 – FY2022-Q32021: 120212022: 12022
Same theme, other companies
対応 to the 2022 Adoption of the Revenue Recognition Accounting StandardA theme 622 companies write about · 16 as a headwind · 2 as a tailwind

123 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 622 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3RestatedAnnual report

    「Because the revenue recognition accounting standard and related standards were applied, “Notes and accounts receivable—trade,” previously presented under “Current assets” in the consolidated balance sheet for the previous consolidated fiscal year, has been presented as part of “Notes and accounts receivable—trade and contract assets” from the first quarter consolidated accounting period.」

    第1四半期から適用した収益認識会計基準に基づく表示方法を継続している。
  2. FY2022-Q1First statedAnnual report

    「「収益認識に関する会計基準」(企業会計基準第29号 2020年3月31日)等を当第1四半期連結会計期間の期首から適用し、約束した財又はサービスの支配が顧客に移転した時点で、当該財又はサービスと交換に受け取ると見込まれる金額で収益を認識することといたしました。これにより、従来は複数の履行義務により構成される契約については、契約に含まれるすべての履行義務を充足した時点で収益を認識しておりましたが、契約に複数の履行義務が含まれる場合には履行義務ごとに充足した時点で収益を認識する処理に変更しております。」

    2021年4月1日から収益認識会計基準を適用し、複数の履行義務を含む契約について履行義務ごとに充足時点で収益を認識する会計方針へ変更した。損益および期首利益剰余金への影響は軽微としている。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Shin Nippon Biomedical Laboratories's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.